Advertisement

Featured in NEJM Journal Watch: Spironolactone Mitigates Rosacea Risk — Physician’s First Watch

Medical News |
November 5, 2013

Featured in NEJM Journal Watch: Spironolactone Mitigates Rosacea Risk

By the NEJM Journal Watch Editors

In a large population-based analysis, spironolactone users had lower-than-expected rates of incident rosacea.

Mark Dahl, a dermatologist for NEJM Journal Watch, reminds readers: "Spironolactone is not FDA approved to treat rosacea. This study assesses the risk for developing rosacea; it does not assess the ability of oral spironolactone to treat rosacea of any subtype."

Reader Comments (1)

IBRAHIM ELSAYAD Physician, Dermatology, mowasat hospital

Journal watch provides very useful information

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement